Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Name: Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
Uploaded: 2022-08-04T14:30:17.799Z
Description: Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.

August 4, 2022

Nicholas J. Short, MD

Video

Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.